These findings suggested that CD276-targeted Dash CAR-T might be a valuable option for pancreatic cancer patients, worthy of further investigation, and provided a time-saving and high-efficacy CAR-T manufacturing approach applicable to other target CAR-T cells. This evidence concerns the gene CD276 and pancreatic neoplasm.